Want to track PNV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PNV is not paying dividends to its shareholders.
The last earnings report, released on Feb 20, 2026, missed the consensus estimates by -0.005%. On average, the company has fell short of earnings expectations by -0.0017%, based on the last three reports.
PolyNovo Limited has completed 1 stock splits, with the recent split occurring on May 03, 2004.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on ASX (AUD).
PolyNovo Limited (PNV) FAQ
On which exchange is it traded?
PolyNovo Limited is listed on ASX.
What is its stock symbol?
The ticker symbol is PNV.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has PolyNovo Limited ever had a stock split?
PolyNovo Limited had 1 splits and the recent split was on May 03, 2004.
PolyNovo Limited Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Bruce Peatey CEO | ASX Exchange | Q7704D107 CUSIP |
| AU Country | 282 Employees | - Last Dividend | 3 May 2004 Last Split | - IPO Date |
Overview
PolyNovo Limited is an innovative company focused on the development of medical devices, with a global presence that includes the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and other international markets. The company’s key product is the NovoSorb Biodegradable Temporising Matrix, a pioneering solution designed for the management of fully debrided clean surgical wounds. Originating as Calzada Limited, the company underwent a rebranding to PolyNovo Limited in November 2014. Incorporated in 1998, PolyNovo has its headquarters in Port Melbourne, Australia, marking its journey from a national entity into a respected player in the global medical devices industry.
Products and Services
- NovoSorb Biodegradable Temporising Matrix: A revolutionary product designed for the temporary closure of large surgical wounds. This biodegradable matrix aids in the management of wounds until they are ready for physiological closure, ensuring a safer and more effective healing process.
- Hernia Devices: PolyNovo is actively involved in the development of devices aimed at hernia repair. This includes solutions for ventral hernia and complex abdominal wall reconstruction, addressing a critical need in surgical interventions for hernia patients.
- NovoSorb Dermal Beta Cell Implant: This innovative implant is designed to host pancreatic islet cells within the skin. Its development represents a potentially significant advancement in the treatment of diabetes, offering a novel approach to islet cell implantation.
- NovoSorb MTX: Aimed at the treatment of complex wounds, NovoSorb MTX is under development to address a broad spectrum of wound types. This product highlights PolyNovo's commitment to expanding its portfolio to meet the diverse needs of wound care.
- Plastics and Reconstructive Device Product: PolyNovo is also developing products in the plastics and reconstructive surgery arena, signaling its entry into this highly specialized sector of medical devices. While specific details are under wraps, the company’s efforts in this area indicate a broadening scope of application for its biodegradable matrix technology.
Contact Information
Address: 320 Lorimer Street
Phone: 61 3 8681 4050
Website: https://polynovo.com
